Institution:
Experimental design developed to detect DNA methylation changes in patient T cells upon CAR transduction
EPICART
Development of a DNA methylation kit for predicting the response to CAR T-cell therapy, , already licensed to Pharmalink
Research Group:
Epigenètica del Càncer
Researcher/s:
Manel Esteller Badosa
Carlos García Prieto
Description:
Value Proposition:
Personalised medicine, cancer epigenetics, leukemia, CAR-T Cell therapy
Aplication areas:
Cancer therapy
Target market:
Pharmaceutical companies
Technology Readiness Level (1-9): 4
Protection:
Patented (EP21382168.9; EP21382815.5; PCT/EP2022/054803)
More information
if you want to know more about this project do not hesitate to contact us